STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARS
  4. [8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event

[8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. reported a leadership change in its commercial organization. On July 13, 2026, the company announced that Aziz Mottiwala will leave his role as Chief Commercial Officer and end his employment with Tarsus on July 15, 2026.

The company stated that Mottiwala is departing to pursue a new opportunity as Chief Executive Officer of a public medical device company. The report is made as a departure of a certain officer under the disclosure requirements for corporate officers.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Announcement date July 13, 2026 Date Tarsus Pharmaceuticals announced the Chief Commercial Officer’s planned departure
Departure effective date July 15, 2026 Date on which the Chief Commercial Officer will leave employment with the company
Company telephone number (949) 418-1801 Registrant’s telephone number listed with the principal executive offices
Chief Commercial Officer financial
"announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer"
A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Securities Exchange Act of 1934 regulatory
"pursuant to Rule 12b-2 of the Securities Exchange Act of 1934"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001819790FALSE00018197902026-07-132026-07-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported) July 13, 2026
_______________
TARSUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
_______________
Delaware
001-39614
81-4717861
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
17700 Laguna Canyon Road, Floor 4
Irvine, CA 92618
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (949) 418-1801
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareTARS
The Nasdaq Global Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tarsus Pharmaceuticals, Inc.
Date: July 13, 2026By:/s/ Bryan Wahl
Bryan Wahl
General Counsel and Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents